Review
Oncology
Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Jun Huang
Summary: Haploidentical stem cell transplantation is an effective alternative donor source for AML patients, with outcomes comparable to traditional transplantation methods for various types of AML. Relapse and infections post haplo-SCT remain key challenges in improving clinical outcomes for AML patients. Areas of active research include relapse prophylaxis, intervention, treatment, as well as infection prevention and therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Kaito Harada, Shohei Mizuno, Shingo Yano, Akiyoshi Takami, Hiroto Ishii, Kazuhiro Ikegame, Yuho Najima, Shinichi Kako, Takashi Ashida, Souichi Shiratori, Shuichi Ota, Makoto Onizuka, Kentaro Fukushima, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. Our retrospective analysis showed that a higher CD3(+) cell count was associated with an increased risk of acute GVHD, and preemptive DLI resulted in better overall response.
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Ting Huang, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: This study compared the clinical outcomes of AML patients with and without TP53 mutations who underwent haplo-HSCT, and found no significant differences in 2-year clinical outcomes between the two groups. Multivariable analysis also showed that TP53 mutations had no significant impact on relapse rate, mortality rate, overall survival, graft-versus-host disease, leukemia-free survival or GvHD-free/relapse-free survival. The findings suggest that patients with AML with TP53 mutations may at least partially benefit from haplo-HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Immunology
Maryam Barkhordar, Amir Kasaeian, Ghasem Janbabai, Hossein Kamranzadeh Fumani, Sahar Tavakoli, Amir Abbas Rashidi, Seied Asadollah Mousavi, Ardeshir Ghavamzadeh, Mohammad Vaezi
Summary: This study evaluated the long-term outcomes of haploidentical peripheral blood stem cell transplantation using the combination of anti-thymocyte globulin and post-transplant cyclophosphamide (ATG/PTCy). The results showed that the ATG/PTCy combination had a lower risk of graft-versus-host disease, but a higher risk of relapse compared to the standard ATG regimen. However, the combination had no significant effect on long-term outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Wen-Jing Yu, Yu-qian Sun, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Yu Wang
Summary: There is no consensus on whether haploidentical hematological stem cell transplantation (haplo-HSCT) at first complete remission (CR1) stage has prognostic advantages over transplantation at second complete remission (CR2) stage for AML patients. This study compared the outcomes of 768 consecutive AML patients who received haplo-HSCT in CR1 and CR2 groups, and found that in the intermediate-risk subgroup, CR1 group had lower transplant-related mortality (TRM) and superior disease-free survival (DFS) and overall survival (OS) compared to CR2 group.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Byung-Sik Cho, Gi-June Min, Silvia Park, Sung-Soo Park, Seung-Hwan Shin, Seung-Ah Yahng, Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Myungshin Kim, Yonggoo Kim, Hee-Je Kim
Summary: This prospective study demonstrated the non-inferiority of Haplo-HSCT to MUD-HSCT for AML in remission, and validated the role of WT1 quantification as an MRD marker. Both groups had similar outcomes in terms of overall and disease-free survival, relapse, non-relapse mortality, and GVHD-free/relapse-free survival.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Carmine Liberatore, Mauro Di Ianni
Summary: The management of relapsed acute myeloid leukemia (AML) post allogeneic hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Hypomethylating agents (HMAs) have become the standard therapeutic approach due to favorable tolerability and their ability to be combined with other anti-leukemic agents. The addition of donor lymphocytes infusions (DLI) generally leads to improved outcomes, while the introduction of novel targeted drugs offers new possibilities in salvage regimens.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Cong Zeng, Yan Chen, Juan Hua, Yi Liu, Ting-ting Cheng, Xia Ma, Xu Chen, Shi-yu Wang, Ya-jing Xu
Summary: This retrospective study analyzed the outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB). Satisfactory results were obtained with high engraftment rates and relatively low rates of transplant-related complications.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Satoshi Yamasaki, Shohei Mizuno, Makoto Iwasaki, Sachiko Seo, Naoyuki Uchida, Miyakoshi Shigesaburo, Nobuaki Nakano, Kazuya Ishiwata, Yasufumi Uehara, Tetsuya Eto, Ken Takase, Toshiro Kawakita, Masatsugu Tanaka, Masashi Sawa, Yuta Katayama, Yuichiro Nawa, Onizuka Makoto, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda, Masamitsu Yanada
Summary: This study analyzed the applications and factors affecting unrelated donor bone marrow transplantation (UR-BMT), unrelated donor cord blood stem cell transplantation (UR-CBT), and haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT) in older patients with acute myeloid leukemia (AML) in Japan. The results showed that overall survival (OS) was superior in the UR-BMT group compared to the other groups. However, in non-complete remission (non-CR) patients, Karnofsky performance status (KPS) <80 at HCT and poor-risk cytogenetics were identified as independent predictors of worse OS. Therefore, KPS <80 may serve as an alternative indicator for non-CR AML patients with poor-risk cytogenetics in the selection of HCT, alternative treatments, or best supportive therapy, and optimal KPS is crucial for the success of HCT.
ANNALS OF HEMATOLOGY
(2023)
Article
Biophysics
Giorgia Battipaglia, Jacques-Emmanuel Galimard, Myriam Labopin, Anna Maria Raiola, Didier Blaise, Annalisa Ruggeri, Yener Koc, Zafer Guelbas, Antonin Vitek, Simona Sica, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Montserrat Rovira, Ivan Moiseev, Massimo Martino, Giovanni Grillo, Mercedes Colorado Araujo, Claude Eric Bulabois, Stephanie Nguyen, Gerard Socie, Mutlu Arat, Jiri Pavlu, Johanna Tischer, Hans Martin, Lucia Lopez Corral, Goda Choi, Edouard Forcade, Andrew McDonald, Fabrizio Pane, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: The study compared Haploidentical (Haplo) HCT with one-antigen mismatched unrelated donor (1Ag-MMUD) HCT for acute myeloid leukemia (AML) patients in complete remission. It found that Haplo groups had higher non-relapse mortality, lower leukemia-free survival, and overall survival compared to 1Ag-MMUD groups. No significant differences were observed for graft-versus-host/relapse-free survival and relapse incidence.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Yu Zhang, Chenjing Ye, Haojie Zhu, Youran Zhuang, Shaozhen Chen, Yingxi Weng, Jinhua Ren, Xiaofeng Luo, Jing Zheng, Xiaoyun Zheng, Jing Li, Lingqiong Lan, Yongxin Xie, Zhongchao Han, Jianda Hu, Ting Yang
Summary: This study investigated the impact of KIR mismatch and KIR alleles on haplo-HSCT outcome in AML patients. The results showed that both KIR ligand mismatch (KLM) and KIR receptor-ligand mismatch (RLM) were associated with a decreased risk of aGVHD and relapse, as well as better overall survival. RLM was more accurate in predicting HSCT outcome than KLM. Patients with a higher number of donor activating KIRs (aKIR) had a lower incidence of aGVHD and relapse. RLM and a high number of donor aKIRs together provided a better donor selection strategy for improving haplo-HSCT outcome in AML patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Xue Han, Jiajia Zhao, Jie Liu, Dan Guo, Huibo Li, Shengjin Fan
Summary: HLA loss is an essential mechanism involved in immune escape and recurrence in acute leukemia after haploidentical transplantation. This study reports a case of high-risk acute myeloid leukemia patient who relapsed within six months after transplantation and had a complete loss of a mismatched HLA haplotype. Haploidentical transplantation combined with umbilical cord blood may trigger relapse of HLA loss.
TRANSPLANT IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yanan Zhai, Prashant Singh, Anna Dolnik, Peter Brazda, Nader Atlasy, Nunzio del Gaudio, Konstanze Dohner, Hartmut Dohner, Saverio Minucci, Joost Martens, Lucia Altucci, Wout Megchelenbrink, Lars Bullinger, Hendrik G. Stunnenberg
Summary: This study explored the clonal heterogeneity of diagnosis and relapse pairs in acute myeloid leukemia patients at genetic and transcriptional levels, revealing the underlying pathways and genes contributing to cancer recurrence. Single cell RNA data showed extensive expression differences between patients and diagnosis-relapse pairs, indicating potential mechanisms leading to therapeutic resistance and AML recurrence.
Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Wen-Xuan Huo, Qi Wen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) was investigated. The study showed that the 3-year cumulative incidence of measurable residual disease occurrence, relapse and non-relapse mortality after HID HSCT was 28.6%, 11.6% and 6.7% respectively. The 3-year probability of event-free survival, leukaemia-free survival (LFS) and overall survival (OS) after HID HSCT was 60.7%, 81.7% and 85.6% respectively.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
